



Company Announcement

Phosphagenics Licenses Diclofenac Gel for Indian Market

2 November 2011, Melbourne, Australia: Melbourne drug delivery technology company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), has licensed TPM/diclofenac, its topical non-steroidal pain formulation, to Themis Medicare Pvt Ltd of Mumbai for the Indian market.

This represents Phosphagenics' first commercial deal in India and its first licensing agreement of its diclofenac product. Under the terms of the agreement, Themis Medicare is committed to pay Phosphagenics an undisclosed up-front fee and double-digit royalty payments on sales.

Themis Medicare is an Indian company that manufactures, formulates and markets its own products throughout India and internationally. It has four state of the art manufacturing facilities.

This licensing deal is an exclusive one for the Indian market with Themis Medicare obligated to launch the over the counter TPM/diclofenac product within 12 months.

Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that works to reduce pain by reducing inflammation. It is used as an active ingredient to reduce pain and inflammation and administered in a tablet form as well as in topical formulations. The most popular topical brand is Voltaren Emulgel™.

In 2009 Phosphagenics announced clinical results that compared its formulation with Voltaren Emulgel™. The Phosphagenics formulation clearly showed more rapid absorption and deeper penetration than Voltaren Emulgel™. More recently Phosphagenics conducted *in vitro* comparative studies demonstrating that its TPM® formulation delivered more diclofenac through human skin than commercial products currently sold into the Indian market.

“This deal represents another endorsement of the superior delivery capabilities of the patented TPM® technology as well as a new revenue source for the company. We expect this to lead to other licensing arrangements for diclofenac in other regions of the world,” said Dr Ogru, Phosphagenics CEO.

The global diclofenac market exceeds US\$1 billion per annum.

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168

PO Box 1415, Clayton South MDC VIC 3169 Australia

Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151

Web: www.phosphagenics.com Email: info@phosphagenics.com

Ends

Enquiries:

Dr Esra Ogru
Chief Executive Officer
Phosphagenics Limited
+61 3 9565 1119

David Segal
Investor Relations Manger
Phosphagenics Limited
+61 3 9565 1103

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

About Phosphagenics

Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® – Targeted Penetration Matrix technology. TPM® is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead product advancing through clinical trials is an oxycodone matrix system for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com
www.elixia.com.au

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168

PO Box 1415, Clayton South MDC VIC 3169 Australia

Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151

Web: www.phosphagenics.com Email: info@phosphagenics.com